Improving Erectile Dysfunction Management Among Asian Men With Diabetes Using the Knowledge Translation Intervention

Ann Fam Med. 2023 Nov-Dec;21(6):502-507. doi: 10.1370/afm.3030.

Abstract

Purpose: Erectile dysfunction (ED) is frequently undermanaged due to communication barriers, particularly among Asian men. We looked at how ED discussion and treatment were affected by the patient's prompt sheet and the Knowledge Translation Tools in the Management of Erectile Dysfunction (LASTED).

Methods: We conducted a quasi-experimental study in a primary care clinic in Kedah, Malaysia involving 120 Asian men with diabetes. In the intervention group, patients were given a prompt sheet to indicate their intention to discuss or receive ED treatment, and physicians were provided with LASTED to assist with ED consultation. The control group patients received standard care from their physicians.

Results: The intervention increased the initiation of ED discussion up to 66.7% compared with 8.3% in the control group. In the intervention group, 57.5% of patients were prescribed phosphodiesterase-5 inhibitors and men with ED of moderate severity were more likely to be prescribed oral ED medication. Use of the LASTED flipchart was associated with prescription of phosphodiesterase-5 inhibitors (P = .011) and patient satisfaction with ED consultation (P <.001).

Conclusion: Our study suggests that using the LASTED flipchart and patient's prompt sheet together may encourage ED conversation and medication prescription particularly when working with Asian men who frequently view ED as a taboo subject.

Keywords: diabetes mellitus; erectile dysfunction; knowledge translation; sexual health.

MeSH terms

  • Cyclic Nucleotide Phosphodiesterases, Type 5 / therapeutic use
  • Diabetes Mellitus* / drug therapy
  • Erectile Dysfunction* / drug therapy
  • Humans
  • Male
  • Phosphodiesterase 5 Inhibitors / therapeutic use
  • Translational Science, Biomedical

Substances

  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Phosphodiesterase 5 Inhibitors